Skip to main content
Premium Trial:

Request an Annual Quote

Affy Shares Up 6.4 Percent Two Days After Upgrade by Cairns

NEW YORK, March 24 (GenomeWeb News) - Shares in Affymetrix were up 6.4 percent since since Tuesday's closing price after an analyst for Cairns & Company yesterday raised the stock to "Above Average" from a "Buy." 


Shares in the world's largest microarray maker were trading at $44.48 in mid-afternoon today, up from $41.79 the day before the analyst upgraded the stock.


The Cairns move comes six days after Thomas Weisel upgaded the shares to "Outperform" from "Peer Perform." The company's stock has since risen $4.84, or 12.2 percent, from its closing price of $39.74 the day before Thomas Weisel's upgrade.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.